SK Bioscience Co

SK Bioscience Co Debt/EBITDA

The Total Debt to EBITDA Ratio of SK Bioscience Co (302440.KS) as of Nov 4, 2026 is -3.76. In the previous year, Total Debt to EBITDA Ratio was -2.96 — a change of 27.15% (lower).

Debt/EBITDA

-3.76

YoY

27.15%

Last updated:

Total Debt to EBITDA Ratio of SK Bioscience Co is 2025 -3.76 . Total Debt to EBITDA Ratio of SK Bioscience Co was 2024 -2.96 . It decreases by 27.15% lower compared to the previous year.

The SK Bioscience Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
37.48 KRW
Jan 1, 2019
15.73 KRW
Jan 1, 2020
2.53 KRW
Jan 1, 2021
0.07 KRW
Jan 1, 2024
-2.96 KRW
Jan 1, 2025
-3.76 KRW
The SK Bioscience Co Debt/EBITDA history
YEARDebt/EBITDAYoY
-3.76+27.15%
-2.96-4,071.20%
0.07-97.05%
2.53-83.91%
15.73-58.04%
37.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SK Bioscience Co Stock analysis

What does SK Bioscience Co do? SK Bioscience Co Ltd is a South Korean biotechnology company headquartered in Seongnam, Gyeonggi-Do. The company went public on March 18, 2021, with its stock listed on the Korean Stock Exchange under the ticker 302440.KS. It operates within the health care sector, specifically in the biotechnology industry. SK Bioscience employs 1,067 people and focuses on the development and distribution of bio and vaccine products. The company distributes its products both domestically and internationally. While specific product names are mentioned in unverified sources, the company is known to be involved in the production of vaccines and infusion solutions. It also engages in technology export business, though detailed information about its technology or export markets is not provided. The company's website is https://www.skbioscience.co.kr/, where further information about its operations and products may be available. SK Bioscience does not disclose specific details about its product lines beyond the general categories of vaccines and infusion solutions, and it does not provide information on acquisitions, founding year, or key personnel. The company's activities are centered around biotechnology and healthcare, with a focus on vaccine development and distribution. Its market presence spans both domestic and international markets, though specific regions or countries are not specified. The company's financial data, including revenue and market capitalization, is not included in the provided information. SK Bioscience is a publicly traded company with a focus on biotechnology and healthcare innovation. SK Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SK Bioscience Co stock

Total Debt to EBITDA Ratio of SK Bioscience Co is -3.76 in 2025.

Total Debt to EBITDA Ratio of SK Bioscience Co changed from -2.96 to -3.76, representing a 27.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio SK Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's SK Bioscience Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SK Bioscience Co

All Key Metrics — SK Bioscience Co